Atorvastatin Calcium + FenofibrateThird Party Manufacturing in India

Atorvastatin Calcium + Fenofibrate works by utilizing two distinct, complementary pathways to address mixed lipid abnormalities, targeting both elevated low-density lipoprotein (LDL) cholesterol and high triglyceride levels.

The Atorvastatin component acts by inhibiting the HMG-CoA reductase enzyme, which decreases hepatic cholesterol synthesis and upregulates low-density lipoprotein receptors to clear LDL cholesterol from circulation. Meanwhile, the Fenofibrate component activates the peroxisome proliferator-activated receptor alpha (PPARα). This activation increases the expression of lipoprotein lipase, which accelerates the clearance of triglyceride-rich very-low-density lipoproteins (VLDL) from the plasma and boosts the synthesis of high-density lipoprotein (HDL) cholesterol.

Unlike statin monotherapy, this combination offers a comprehensive lipid-modulating effect that simultaneously lowers LDL, significantly reduces triglycerides, and raises HDL levels. It is highly effective for patients with mixed dyslipidemia who remain at high cardiovascular risk despite standard statin therapy.

Therapeutic Uses

Atorvastatin Calcium + Fenofibrate is prescribed for the treatment of:

• Mixed Dyslipidemia: Treats patients with elevated LDL cholesterol, elevated triglycerides, and low levels of HDL cholesterol.
• Severe Hypertriglyceridemia: Helps lower extremely high levels of triglycerides to prevent complications like pancreatitis.
• Cardiovascular Risk Reduction: Prescribed to diabetic patients and individuals with metabolic syndrome who have complex lipid profiles and high heart disease risks.

Why Manufacturers Choose Atorvastatin Calcium + Fenofibrate

Statin monotherapy is often insufficient for patients with mixed dyslipidemia or diabetic dyslipidemia, which require addressing both high triglycerides and LDL cholesterol. Combining Atorvastatin and Fenofibrate into a single fixed-dose tablet increases compliance by eliminating pill burden. The massive prevalence of diabetic dyslipidemia makes this combination a high-volume product in cardiac and diabetic marketing divisions.

This makes this combination a highly requested formulation for third party manufacturing in India, with consistent demand from diabetic and cardiac PCD franchises.